Bone gel sheet composition and method of manufacture

Information

  • Patent Grant
  • 11253629
  • Patent Number
    11,253,629
  • Date Filed
    Monday, August 15, 2016
    8 years ago
  • Date Issued
    Tuesday, February 22, 2022
    2 years ago
Abstract
A bone gel composition consists of cortical bone. The cortical bone is made from cut pieces freeze-dried then ground into particles and demineralized then freeze-dried. A volume of the particles is placed in a solution of sterile water to create a mixture, the water volume being at least twice the particle volume, the mixture is autoclaved under heat and pressure to form a gelatin, the resulting bone gel is formed into sheets having a thickness (t).
Description
TECHNICAL FIELD

This invention is a demineralized bone composition made in the form of a gel. More specifically, a composition that can be formed as a gel or gelatinous composition shaped into flat sheets and a method of manufacture and use of said composition.


BACKGROUND OF THE INVENTION

The manufacture and use of bone allografts from bone tissue is well known. The use of particles of various specific sizes and distributions have been determined to have beneficial characteristics for new bone growth in the treatment of osseous defects and bone voids.


The issue of getting the repair composition to stay in position has been addressed for various formulations made into malleable paste or putty by the addition of collagen or other gelatinous materials.


The present invention provides an improvement over those prior art materials by providing a bone gel that is conformable into sheets and configured to be shaped so it can be added to autograft or allograft bone particles to make a moldable bone product.


SUMMARY OF THE INVENTION

A bone gel composition consists of cortical bone. The cortical bone is made from cut pieces freeze-dried then ground into particles and demineralized then freeze-dried. A volume of the particles is placed in a solution of sterile water to create a mixture, the water volume being at least twice the volume of the freeze-dried particles, the mixture is autoclaved under heat and pressure to form a gelatin, the resulting bone gel is formed into sheets having a thickness (t) and frozen for later use, preferably frozen at a temperature of −20 to −80 degrees C. The cortical bone has the cut pieces having a width, a length and a thickness in the range of 1 to 4 mm. The cortical bone pieces are ground to a particle size up to 125 microns.


A method of making a bone gel composition consisting of cortical bone comprises the steps of: preparing cortical bone by cutting the cortical bone into pieces, freeze-drying the pieces and then grinding into particles and demineralizing the ground particles and freeze-drying the demineralized ground particles to form DBM particles; autoclaving a volume of the DBM particles mixed with sterile water in a 1:2 ratio by volume for a predetermined time at a pre-set temperature and pressure to form a gelatin; shaping the bone gel into a sheet having the thickness (t); cooling the gelatin to form a bone gel; cutting the sheet into small sheets of a polygonal shape, if necessary, preferably of a circular, square or a rectangular shape wherein the thickness is between 1 and 10 mm, preferably between 2 and 3 mm and packaging the resulting bone gel and storing the packaged bone gel.


Definitions

Cohesiveness is defined as the capacity of DBM aseptic paste to maintain its shape while immersed in normal saline or water for a minimum of one minute.


DBM—Demineralized Bone Matrix.


Freeze Dried/Lyophilized—Tissue dehydrated for storage by conversion of the water content of frozen tissue to a gaseous state under vacuum that extracts moisture.


Malleability is the ability to be molded into different shapes with no visible cracks.


Normal Saline—0.9% Sodium Chloride Solution.


PBS—Phosphate Buffered Saline.


SRI—an equipment sterilization company.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be described by way of example and with reference to the accompanying drawings in which:



FIG. 1 shows a photograph of the bone gel composition in a container and packaged in a clear sealed bag.



FIG. 2 is a photograph of the bone gel composition removed from the packaging with the container lid removed and open.



FIG. 3 is a photograph of the bone gel composition being removed from the container.



FIG. 4 is a photograph of the bone gel composition removed from the container.



FIG. 5 is a photograph of the bone gel composition being worked with.



FIG. 6 is another photograph of the bone gel composition being worked with.



FIG. 7 is a schematic illustration of the bone gel product manufacturing process outline.



FIG. 8 is a schematic illustration of the subprocess of cutting and freeze-drying.



FIG. 9 is a schematic illustration of the subprocess of grinding, demineralization, freeze-drying.



FIG. 10 is a schematic illustration of the subprocess of bone gel preparation.



FIG. 11 is a schematic illustration of the subprocess of packaging.



FIG. 12 is a photograph of the bone gel composition formed as a sheet material of the present invention.



FIG. 13A is photograph of the sheet material being cut into rectangular or square polygonal shapes.



FIG. 13B is a photograph of the rectangular or square shaped sheet being put in a bag for packaging.



FIG. 14A is a photograph of the bone gel composition shaped as a round or circular sheet by being subprocessed in a round mold or container.



FIG. 14B is a photograph of the bone gel round sheet being removed from the container.



FIG. 14C is a photograph of the bone gel round sheet after being placed in a packaging bag.





DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses the manufacturing of bone gel derived from human cadaveric cortical bone. Cortical bone is obtained from male or female donors within suitable age groups. Full body donors with no joint replacements are preferred. The donors' medical and social history are screened for medical conditions such as osteoporosis and alcohol abuse, which may hinder the intended purpose of the final product. At ambient temperature, bone gel is gelatinous and cohesive. Therefore, it is intended to serve as a binding agent. Bone gel is ready for use or can be mixed with other products.


The bone gel product is entirely derived from cortical bone. The cortical bone is aseptically recovered, cleaned, cut, morselized or shaved, ground, sieved at different sizes, demineralized and freeze-dried to obtain cortical bone particles. Freeze dried, demineralized, ground cortical bone is then mixed with water. The mix is pressurized and heated to form the Bone Gel. Final Bone Gel 10 products of 2 cc, 4 cc or 8 cc are distributed into containers 20, packaged in final packaging 50, as shown in FIG. 1, and stored at room temperature or frozen until distribution to the end user. The amount of bone gel can vary depending on the application.


The overall manufacturing process for the Bone gel product can be seen in FIG. 7. The input of the process is the donated and approved for processing aseptic human cadaveric cortical bone immediately frozen after recovery. Once the cortical bone has been processed, the output is the packaged Bone gel product. The process itself has been divided into four subprocesses with their own respective inputs and outputs.


The cutting subprocess is schematically shown in FIG. 8.


Prior to cutting the donated and approved for processing human cadaveric cortical bone, all extraneous material such as muscle fibers, adipose tissue, and periosteum are removed from the tissue. Bones are then rinsed a minimum of 3 times with physiological grade Normal Saline (0.9% Sodium Chloride). Using a band saw, the bones are cut in a manner that the cortical and cancellous portions are separated.


The cortical bone is then cut into small pieces using a band saw. The small pieces are rinsed a minimum of three times in Normal Saline and then placed into a metal container with fresh Normal Saline. The container is aseptically wrapped, placed on a shaker and mechanically agitated for 5 to 10 minutes. The bone tissue is then morselized into 1 to 4 mm length and width pieces, respectively, using a morselizer. The tissue is rinsed again a minimum of three times with Normal Saline in order to remove any remnants of blood and/or fat deposits. The bone pieces are rinsed with hydrogen peroxide for no more than 10 minutes to remove fat/blood. The bone pieces are rinsed a minimum of three times with sterile water to remove any residual hydrogen peroxide. Then, the bone tissue is placed in a metal container and stored at −80° C. The frozen bone tissue is freeze dried with a cycle set for 33 hours and 50 minutes. It is understood the timing, ratios and volumes can vary based on the equipment and procedures used and the above is exemplary of the preferred process for the inventors' equipment.


The Grinding-Demineralization subprocess is shown in FIG. 9.


Once the freeze drying cycle is completed, the cortical bulk is ground and sieved to obtain particle sizes of up to 125 μm, typically 25 to 125 μm. The particulate tissue is demineralized by addition of 0.6 HCL solution at a 20:1 ratio (20 ml of 0.6 HCL to 1 g of bone). The solution containing the tissue is placed on a magnetic stir plate for 19 minutes. After decanting the liquid, the particulate tissue is mixed with sterile water at a 20:1 ratio (20 ml of sterile water to 1 g of bone). The solution containing the tissue is placed on a magnetic stir plate for 4 minutes. The process of decanting, mixing and incubating for 4 minutes is repeated with PBS solution. After decanting the PBS, the particulate tissue is mixed with sterile water at a 20:1 ratio (20 ml of sterile water to 1 g of bone). The solution containing the tissue is placed on a magnetic stir plate for 9 minutes. The water waste solution is decanted and the demineralized particulate tissue is stored at −80° C. The frozen, demineralized particulate tissue is freeze dried for 33 hours 50 minutes. At the end of the freeze drying process, samples can be collected for residual moisture and residual calcium testing. It is understood the timing, ratios and volumes can vary based on the equipment and procedures used and the above is exemplary of the preferred process for the inventors' equipment.


The Bone Gel Preparation subprocess is shown in FIG. 10.


The demineralized, freeze-dried cortical bone particles can be divided into groups of 100 cc, approximately. Each group is placed in a Pyrex glass bottle and mixed with only or exclusively sterile water. The ratio of sterile water to particles is 2:1 by volume. In order to prepare Bone Gel, the mix is autoclaved for 1.25 hours. The autoclaving process includes conditioning (15 minutes), exposure (30 minutes) and drying (30 minutes). Temperature during the exposure step is 121.1° C. and the pressure is 30.15 psi. After autoclaving is completed, the Bone Gel is aliquoted to jars. It is understood the timing, ratios and volumes can vary based on the equipment and procedures used and the above is exemplary of the preferred process for the inventors' equipment.


The Packaging subprocess is shown in FIG. 11.


The Bone Gel is packaged in closed containers. The containers have a lid insert 22 secured by a cap 24 or is packaged in tear pouches 52 followed by outer packing. The packaged final products are stored at room temperature or frozen until they are distributed to the end user. Batch release is contingent upon final culture results.


The bone gel composition is designed to be mixed with allograft or autograft bone particles, strands, growth factors, bone putty, bone paste, cells, or other bone growth enhancing products.


With reference to FIG. 12, the bone gel composition 10 is shown formed as a thin sheet 100 of material having a thickness t. The bone gel 10, as shown in FIG. 12, was flattened into a substantially rectangular sheet approximately 20 cm in width by approximately 25 to 27 cm in length. After the material was formed in large rectangular shapes, it can then be cut into smaller polygonal shapes, as illustrated in FIG. 13A. In FIG. 13A, a corner of the bone gel sheet 100 has been cut into a substantially square shape and, as shown in FIG. 13B, this substantially square shape is then placed in a sterile package 51 for later use.


In another configuration, small glass containers 21 can be utilized wherein the bone gel 10 is pressed into the circular shaped container 21 and flattened to the desired thickness t, as shown in FIG. 14A. Once properly sized and flattened, the material then can be lifted from the container 21, as shown in FIG. 14B. Once the material has been removed from the container 21, it then can simply be put in a sterile package 52, as illustrated in FIG. 14C.


The ability to take the bone gel 10 and flatten it into polygonal shapes such as square, rectangular, circular or any other desired shape, makes the material easier to handle for its particular applications allowing the surgeon to pick up a small, well defined structure and to place it in the area of the bone to be repaired or healed using this sheet like material 100. As shown, the material can be taken from the package and other material such as stem cells or other medicants can be added to the material to assist in its use in bone defect repairs.


Variations in the present invention are possible in light of the description of it provided herein. While certain representative embodiments and details have been shown for the purpose of illustrating the subject invention, it will be apparent to those skilled in this art that various changes and modifications can be made therein without departing from the scope of the subject invention. It is, therefore, to be understood that changes can be made in the particular embodiments described, which will be within the full intended scope of the invention as defined by the following appended claims.

Claims
  • 1. A bone gel composition consisting of cortical bone made from cut pieces of cortical bone which has been freeze dried, the freeze dried cut pieces are then ground into particles of a size up to 125 microns and then demineralized by the addition of 20 ml of 0.6 HCL to 1 gram of bone, decanted, then addition of plain sterile water at a 20:1 ratio and decanted and stored at −80 degrees C., the ground demineralized particles are then freeze-dried, wherein a volume of the freeze-dried demineralized particles is placed in a solution of only or exclusively sterile water to create a mixture, the water volume being at least twice the volume of the particles, the mixture consisting of sterile water and the freeze dried demineralized particles is autoclaved under heat and pressure to form a gelatin, the resulting bone gel is formed into sheets having a thickness (t) in the range of 1 to 10 mm and formed into a circular, round or a polygonal shape and frozen for later use.
  • 2. The bone gel composition of claim 1 wherein the polygonal shape is a square or rectangle.
  • 3. The bone gel composition of claim 1 wherein the polygonal shape is any other multi-sided shape.
  • 4. The bone gel composition of claim 1 wherein the thickness (t) is in the range of 2 to 3 mm.
  • 5. The bone gel composition of claim 2 wherein the rectangle has a predetermined width and a predetermined length.
  • 6. The bone gel composition of claim 1 wherein the cortical bone has the cut pieces having a width, a length and a thickness in the range of 1 to 4 mm for each width, length and thickness.
RELATED APPLICATIONS

This application is a continuation in part of U.S. application Ser. No. 15/136,383 filed on Apr. 22, 2016 entitled, “Bone Gel Composition And Method Of Manufacture”.

US Referenced Citations (50)
Number Name Date Kind
3458397 Myers et al. Jul 1969 A
4172128 Thiele et al. Oct 1979 A
4440750 Glowacki et al. Apr 1984 A
5073373 Oleary et al. Dec 1991 A
5236456 Oleary et al. Aug 1993 A
5486359 Caplan et al. Jan 1996 A
5490937 vanReis Feb 1996 A
5531791 Wolfinbarger Jul 1996 A
5733542 Haynesworth et al. Mar 1998 A
6432436 Gertzman et al. Aug 2002 B1
6437018 Gertzman et al. Aug 2002 B1
6458375 Gertzman et al. Oct 2002 B1
6576249 Gendler et al. Jun 2003 B1
RE38522 Gertzman et al. May 2004 E
6911212 Gertzman et al. Jun 2005 B2
6998135 Sunwoo et al. Feb 2006 B1
7015037 Furcht et al. Mar 2006 B1
7019192 Gertzman et al. Mar 2006 B2
7045141 Merboth et al. May 2006 B2
7067123 Gomes et al. Jun 2006 B2
RE39587 Gertzman et al. Apr 2007 E
7488348 Truncale et al. Feb 2009 B2
7659118 Furcht et al. Feb 2010 B2
7847072 Thorne Dec 2010 B2
7879103 Gertzman et al. Feb 2011 B2
RE42208 Truncale et al. Mar 2011 E
7901457 Truncale et al. Mar 2011 B2
8075881 Verfaillie et al. Dec 2011 B2
RE43258 Truncale et al. Mar 2012 E
8221500 Truncale et al. Jul 2012 B2
8292968 Truncale et al. Oct 2012 B2
8354370 Kopen et al. Jan 2013 B2
8394419 Borden Mar 2013 B2
8834928 Truncale et al. Sep 2014 B1
9138508 Borden Sep 2015 B2
9138509 Sunwoo et al. Sep 2015 B2
9192695 Shi Nov 2015 B2
20030059414 Ho et al. Mar 2003 A1
20040058412 Ho et al. Mar 2004 A1
20050181502 Furcht et al. Aug 2005 A1
20060004189 Gandy Jan 2006 A1
20070049739 Troxel Mar 2007 A1
20070524177 Ho et al. Sep 2007
20080008766 Talton Jan 2008 A1
20080281431 Missos Nov 2008 A1
20130195810 Crawford et al. Aug 2013 A1
20140005793 Koford et al. Jan 2014 A1
20140030235 Varney et al. Jan 2014 A1
20150012107 Koford et al. Jan 2015 A1
20160030639 Shi Feb 2016 A1
Non-Patent Literature Citations (4)
Entry
Chu Chang Chua, Deborah Ceiman, and Roger L. Ladda; “Transforming Growth Factors Released From Kirsten Sarcoma Virus Transformed Cells Do Not Compete for Epidermal Growth Factor Membrane Receptors”; Journal of Cellular Physiology 117:116-122 (1983).
Yawei Liua, Anders Kalenb, Olof Ristob & ; “Time- and pH-dependent release of PDGF and TGF-ß from platelets <emph type=” 2“>in vitro</emph>”; pp. 233-237 Platelets vol. 14, Issue 4, 2003 ; Published online: Jul. 7, 2009.
Trinity Elite, product, sales brochure, TT-1515, Orthofix Holdings Inc, Oct. 2015.
Osteocel bone graft web page, http://www.nuvasive.com/patient-solutions/nuvasive-integrated-surgical-solutions/osteocel-bone-graft/; 2016.
Related Publications (1)
Number Date Country
20170304495 A1 Oct 2017 US
Continuation in Parts (1)
Number Date Country
Parent 15136383 Apr 2016 US
Child 15236807 US